The AstraZeneca share price is at all-time highs. Should investors be wary?

Shares of AstraZeneca plc (LON: AZN) look too expensive to me right now.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Amid a choppy market environment, shares of AstraZeneca (LSE: AZN) are performing extremely well. But is this a reason to buy them at their current price? Let’s examine the reasons behind the stock’s performance, as well as whether the current valuation represents an attractive investment opportunity.

Recent successes

Although the last year was an up and down period for AstraZeneca shareholders, patient investors were rewarded with a strong trading update in July. Priced at 7,327p a share, the stock is currently trading at all-time highs, and it’s easy to see why. Product sales were up 17% in the first half of 2019, and total revenue increased by 14%. 

Both revenue and earnings per share beat analysts’ expectations — the former by $251m (£207m) and the latter by $0.13/share (£0.11/share). This outperformance has driven the stock higher by over 15% since the release of the earnings report. 

Drug sales are on the rise

Over the last few years, AstraZeneca has been increasing its investment in its oncology division, and these trading results are evidence of that. Revenue from the oncology segment as a whole grew by 58% in the first half of 2019. These increases were led by lung cancer drug Tagrisso (£1.16 bn) and ovarian cancer treatment Lynparza (£429m), as well as Imfinzi (£547m), prescribed for bladder and urinary tract cancers. 

A few months ago I wrote that CEO Pascal Soriot deserves a lot of credit for AstraZeneca’s much-improved results. It was his vision to move the company to focus on oncology treatment, and this strategy seems to be bearing fruit. Nevertheless, I believe that from an investment standpoint, the business is just too expensive to buy.

Too rich for my blood

Shares of AstraZeneca currently trade at a forward price-to-earnings ratio of 24, well above the PE ratio for the FTSE 100 as a whole, which stands at 15.6. Moreover, it yields a dividend of 3.18%, which is also below the FTSE 100 average (4.74%). And as my colleague Roland Head points out, the company’s net debt has risen significantly over the last four years — from £6.43bn to £13.44bn. He believes that management’s desire to maintain the dividend at current levels has forced it to rely on debt to fund investment, and I agree.

Companies that have above-average valuations tend to underperform, statistically speaking. This is particularly true in times of higher volatility, as has been the case in recent months. When everything is falling, those who bought highest will suffer the most pain. 

There is also the nagging uncertainty surrounding how Brexit will affect the entire pharmaceutical industry. If a no-deal scenario does materialise, that could seriously impact the ability of AstraZeneca (and other companies in the sector) to export drugs to the European Union. I believe that the market is not accurately pricing in this possibility, and for these reasons I’ll be staying away from this stock. 

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Stepan Lavrouk owns no shares mentioned. The Motley Fool UK has recommended AstraZeneca. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

Could the JD Sports Fashion share price double in the next five years?

The JD Sports Fashion share price has nearly halved in the past five years. Our writer thinks a proven business…

Read more »

Bus waiting in front of the London Stock Exchange on a sunny day.
Investing Articles

If interest rate cuts are coming, I think these UK growth stocks could soar!

Falling interest could be great news for UK growth stocks, especially those that have been under the cosh recently. Paul…

Read more »

Investing Articles

Are these the best stocks to buy on the FTSE right now?

With the UK stock market on the way to hitting new highs, this Fool is considering which are the best…

Read more »

Petrochemical engineer working at night with digital tablet inside oil and gas refinery plant
Investing Articles

Can the Centrica dividend keep on growing?

Christopher Ruane considers some positive factors that might see continued growth in the Centrica dividend -- as well as some…

Read more »

Smiling family of four enjoying breakfast at sunrise while camping
Investing Articles

How I’d turn my £12,000 of savings into passive income of £1,275 a month

This Fool is considering a strategy that he believes can help him achieve a stable passive income stream with a…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

2 top FTSE 250 investment trusts trading at attractive discounts!

This pair of discounted FTSE 250 trusts appear to be on sale right now. Here's why I'd scoop up their…

Read more »

Smiling young man sitting in cafe and checking messages, with his laptop in front of him.
Investing Articles

3 things that could push the Lloyds share price to 60p and beyond

The Lloyds share price has broken through 50p. Next step 60p? And then what? Here are some thoughts on what…

Read more »

Young female business analyst looking at a graph chart while working from home
Investing Articles

£1,000 in Rolls-Royce shares a year ago would be worth this much now

Rolls-Royce shares have posted one of the best stock market gains of the past 12 months. But what might the…

Read more »